# Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

> **NCT01688830** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 157 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** BI 655075
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01688830
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688830, "Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01688830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*